David George Huntsman
#128,976
Most Influential Person Now
David George Huntsman's AcademicInfluence.com Rankings
David George Huntsmanphilosophy Degrees
Philosophy
#6182
World Rank
#9178
Historical Rank
Logic
#3373
World Rank
#4520
Historical Rank
David George Huntsmanbiology Degrees
Biology
#8370
World Rank
#11435
Historical Rank
Computational Biology
#158
World Rank
#158
Historical Rank
Genetics
#834
World Rank
#927
Historical Rank
Download Badge
Philosophy Biology
David George Huntsman's Degrees
- PhD Genetics Stanford University
- Doctorate Medicine University of California, San Francisco
Why Is David George Huntsman Influential?
(Suggest an Edit or Addition)David George Huntsman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
- The Immune Landscape of Cancer (2018) (2766)
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers (2012) (1807)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- ARID1A mutations in endometriosis-associated ovarian carcinomas. (2010) (1450)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution (2009) (1115)
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. (2011) (1043)
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies (2010) (1025)
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies (2008) (795)
- Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. (2002) (788)
- Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
- Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies (2012) (738)
- Mutation of FOXL2 in granulosa-cell tumors of the ovary. (2009) (661)
- Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution (2014) (566)
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers (2011) (554)
- deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data (2011) (549)
- Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research (2010) (524)
- Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. (2012) (509)
- Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. (2015) (506)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- A clinically applicable molecular-based classification for endometrial cancers (2015) (486)
- Familial gastric cancer: overview and guidelines for management* (1999) (483)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers (2015) (461)
- EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer (2003) (441)
- Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer (2017) (434)
- Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. (2007) (413)
- A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. (2006) (412)
- Use of immunohistochemical markers can refine prognosis in triple negative breast cancer (2007) (400)
- Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. (2012) (396)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Cancer‐Associated Mutations in Endometriosis without Cancer (2017) (375)
- Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling (2013) (374)
- Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria (2004) (374)
- Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer (2007) (350)
- Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. (2013) (339)
- Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. (1998) (333)
- Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas (2010) (327)
- Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series (2018) (324)
- Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. (2001) (320)
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities (2008) (310)
- TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data (2014) (289)
- Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. (2008) (278)
- Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 (2014) (271)
- Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer (2016) (270)
- Use of mutation profiles to refine the classification of endometrial carcinomas (2012) (268)
- Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. (2009) (264)
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss (2009) (261)
- Model of the early development of diffuse gastric cancer in E‐cadherin mutation carriers and its implications for patient screening (2004) (258)
- A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia (2013) (253)
- FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival (2007) (248)
- Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. (2014) (246)
- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received (2010) (241)
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer (2017) (237)
- Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index (2006) (235)
- Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer (2018) (233)
- The disparate origins of ovarian cancers: pathogenesis and prevention strategies (2016) (232)
- Gastric cancer: New genetic developments (2005) (230)
- 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma (2012) (229)
- IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer (2011) (225)
- DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer (2012) (223)
- Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas (2011) (220)
- Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research (2013) (220)
- SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors (2010) (220)
- A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary (2009) (212)
- Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma (2004) (210)
- Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. (2011) (203)
- Germline CDH1 deletions in hereditary diffuse gastric cancer families (2009) (202)
- Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers (2007) (201)
- PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. (2009) (200)
- Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. (2006) (200)
- Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles (2014) (199)
- Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. (2003) (195)
- Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. (2016) (191)
- The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas (2009) (191)
- Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes (2017) (189)
- HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy (2009) (189)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers (2011) (187)
- Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome (2011) (185)
- Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors (2010) (185)
- Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases (2007) (184)
- Germline E-cadherin mutations in familial lobular breast cancer (2007) (184)
- A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability (2000) (183)
- Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas (2013) (182)
- Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides (2007) (180)
- Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management (2005) (178)
- CDH1 Truncating Mutations in the E-Cadherin Gene: An Indication for Total Gastrectomy to Treat Hereditary Diffuse Gastric Cancer (2007) (177)
- Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. (2002) (173)
- Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer (2013) (167)
- Screening E‐cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred (2002) (167)
- Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 Rearrangement (2012) (165)
- PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2 (2012) (165)
- Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type (2015) (164)
- Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer (2008) (161)
- An α‐E‐catenin (CTNNA1) mutation in hereditary diffuse gastric cancer (2013) (160)
- Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression (2004) (160)
- Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma (2010) (160)
- ARID1A-mutated ovarian cancers depend on HDAC6 activity (2017) (160)
- Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. (2003) (159)
- Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. (2009) (157)
- Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. (2008) (157)
- Type Iγ phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with μ1B adaptin (2007) (155)
- p63 Expression in Lung Carcinoma: A Tissue Microarray Study of 408 Cases (2004) (152)
- An Immunohistochemical Algorithm for Ovarian Carcinoma Typing (2016) (152)
- Prophylactic total gastrectomy for familial gastric cancer. (2001) (151)
- BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma (2012) (151)
- The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas (2010) (150)
- Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. (2015) (148)
- Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry (2002) (148)
- Hereditary diffuse gastric cancer: updated clinical practice guidelines. (2020) (145)
- Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. (2015) (145)
- Hereditary diffuse gastric cancer (2002) (144)
- Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study (2010) (144)
- A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis (2007) (144)
- Amplification of 11q13 in ovarian carcinoma (2008) (144)
- The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis (2004) (140)
- Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. (2016) (139)
- Risk-reducing Total Gastrectomy for Germline Mutations in E-cadherin (CDH1): Pathologic Findings With Clinical Implications (2008) (137)
- FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary (2011) (137)
- Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. (1994) (134)
- IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype (2009) (127)
- Hereditary diffuse gastric cancer: association with lobular breast cancer (2007) (127)
- Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes (2015) (126)
- FOXA1 is an independent prognostic marker for ER-positive breast cancer (2012) (124)
- Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis (2016) (123)
- Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes (2008) (123)
- Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment (2007) (122)
- Subtype‐specific mutation of PPP2R1A in endometrial and ovarian carcinomas (2011) (122)
- Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer: Utility of a Histology-Based Referral Strategy (2012) (121)
- Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. (2008) (121)
- Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. (2010) (120)
- Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden (2015) (119)
- Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival (2005) (119)
- Molecular pathology of cancer (1997) (118)
- Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. (2015) (117)
- A fluorescence in situ hybridization study of ETV6‐NTRK3 fusion gene in secretory breast carcinoma (2004) (116)
- Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival (2010) (116)
- Frequency of Known Gene Rearrangements in Endometrial Stromal Tumors (2011) (114)
- Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. (2003) (114)
- MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines (1999) (114)
- Costs and Benefits of Opportunistic Salpingectomy as an Ovarian Cancer Prevention Strategy (2015) (113)
- Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas (2016) (112)
- Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. (2002) (111)
- Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. (2010) (111)
- Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients (2004) (110)
- Interpretation of p53 Immunoreactivity in Endometrial Carcinoma: Establishing a Clinically Relevant Cut-Off Level (2004) (107)
- Identification of sister chromatids by DNA template strand sequences (2010) (106)
- Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms (2015) (106)
- The role of the fallopian tube in ovarian cancer. (2012) (105)
- Prophylactic Total Gastrectomy (PTG) for Hereditary Diffuse Gastric Cancer (HDGC): The Newfoundland Experience with 23 Patients (2009) (105)
- Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants (2018) (104)
- Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade (2007) (104)
- Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas (2013) (101)
- Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma (2010) (100)
- Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases (2008) (100)
- MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary (2009) (99)
- Calculator for ovarian carcinoma subtype prediction (2011) (99)
- Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA/RNA extraction techniques. (2012) (99)
- Loss and Recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation Is a Mechanism Involved in Epithelial-Mesenchymal-Epithelial Transitions (2012) (99)
- DNA hypermethylation within TERT promoter upregulates TERT expression in cancer (2018) (98)
- Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours (2005) (98)
- Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers (2015) (98)
- The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell–cell adhesion and to suppress invasion (2003) (97)
- Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. (2010) (97)
- The driver landscape of sporadic chordoma (2017) (96)
- Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. (1999) (95)
- Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. (2005) (94)
- Systematic analysis of somatic mutations impacting gene expression in 12 tumour types (2015) (92)
- The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors (2009) (91)
- Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers (2012) (91)
- Oncogenic Mutations in Histologically Normal Endometrium: The New Normal? (2019) (90)
- Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers (2010) (90)
- E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. (2003) (90)
- Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. (2006) (89)
- Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo (2005) (89)
- Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. (2012) (88)
- Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research (2016) (85)
- Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. (2020) (84)
- The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers (2008) (83)
- Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers (2011) (83)
- Population Distribution of Lifetime Risk of Ovarian Cancer in the United States (2015) (80)
- De novo expression of CD44 variants in sporadic and hereditary gastric cancer (2010) (79)
- Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity (2003) (79)
- The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. (2016) (77)
- Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts (2010) (77)
- MDM2 protein expression is a negative prognostic marker in breast carcinoma (2006) (76)
- Targeted mutation analysis of endometrial clear cell carcinoma (2015) (76)
- Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis (2008) (75)
- FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines (2013) (73)
- The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. (2013) (73)
- Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer (2007) (72)
- P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer (2011) (71)
- Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas (2016) (71)
- Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification (2017) (70)
- Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
- Focal amplification and oncogene dependency of GAB2 in breast cancer (2010) (70)
- The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type (2017) (70)
- Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma (2005) (70)
- Rare cancers: a sea of opportunity. (2016) (69)
- Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium (2013) (69)
- Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. (2005) (69)
- A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation (2014) (68)
- Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma (2007) (67)
- Shared heritability and functional enrichment across six solid cancers (2018) (67)
- Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK) (2008) (66)
- Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of HNF‐1β and oestrogen receptor (2014) (65)
- KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies (2010) (65)
- Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival (2004) (65)
- Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study (2014) (65)
- Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. (2008) (65)
- Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status (2020) (65)
- In‐depth molecular profiling of the biphasic components of uterine carcinosarcomas (2015) (64)
- NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis (2005) (64)
- Endometrial Stromal Sarcomas With Sex Cord Differentiation Are Associated With PHF1 Rearrangement (2013) (63)
- Evolutionary concepts in biobanking - the BC BioLibrary (2009) (63)
- Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers (2015) (63)
- Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. (2006) (63)
- L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile (2018) (63)
- Critical molecular abnormalities in high-grade serous carcinoma of the ovary (2008) (63)
- Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup (2017) (63)
- Iatrogenic endometriosis harbors somatic cancer-driver mutations (2018) (63)
- Does massively parallel DNA resequencing signify the end of histopathology as we know it? (2010) (62)
- Prognostic gene expression signature for high-grade serous ovarian cancer (2020) (61)
- Tumor microsatellite instability in early onset gastric cancer. (2005) (61)
- Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin? (2017) (61)
- Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. (2019) (60)
- Germline Mutations in MAP3K6 Are Associated with Familial Gastric Cancer (2014) (60)
- Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy (2010) (60)
- Familial rhabdoid tumour 'avant la lettre'—from pathology review to exome sequencing and back again (2013) (60)
- HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival: A Study of 4046 Patients (2010) (59)
- Podocalyxin: a marker of blasts in acute leukemia. (2005) (59)
- Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. (2005) (58)
- CAMK1D amplification implicated in epithelial–mesenchymal transition in basal‐like breast cancer (2008) (57)
- Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers (2018) (57)
- CDH1 c‐160a promotor polymorphism is not associated with risk of stomach cancer (2002) (57)
- The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer (2012) (57)
- Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data (2007) (57)
- Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer (2010) (55)
- Adult-type granulosa cell tumors and FOXL2 mutation. (2009) (55)
- The prognostic significance of elongation factor eEF1A2 in ovarian cancer. (2008) (55)
- Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer (2011) (54)
- The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors12 (2015) (53)
- BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received (2010) (53)
- Fluorescence In Situ Hybridization for the Detection of t(X;18)(p11.2;q11.2) in a Synovial Sarcoma Tissue Microarray Using a Breakapart-Style Probe (2005) (52)
- ESR1 gene amplification in breast cancer: a common phenomenon? (2008) (52)
- Low-grade serous ovarian cancer: State of the science. (2020) (52)
- Osteopontin expression correlates with melanoma invasion. (2005) (51)
- Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary (2017) (50)
- Histotype classification of ovarian carcinoma: A comparison of approaches. (2018) (50)
- Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development (2007) (50)
- Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study (2018) (50)
- Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma (2016) (50)
- CDH1/E-cadherin germline mutations in early-onset gastric cancer (2006) (49)
- The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome (2018) (48)
- Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics (2013) (48)
- Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. (2016) (47)
- Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. (2011) (47)
- Class I HDAC inhibitors enhance YB‐1 acetylation and oxidative stress to block sarcoma metastasis (2019) (47)
- Fluorescent in situ hybridization on tissue microarrays: challenges and solutions (2007) (47)
- p53 is positively regulated by miR-542-3p. (2014) (47)
- Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small‐cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics (2016) (46)
- A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. (2018) (45)
- Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice (2018) (44)
- Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (2018) (44)
- Synthesis of diagnostic quality cancer pathology images by generative adversarial networks (2020) (43)
- Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition (2018) (43)
- Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial (2011) (43)
- Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies (2017) (43)
- Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors (2013) (43)
- Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers (2010) (42)
- Molecular profiling and molecular classification of endometrioid ovarian carcinomas. (2019) (42)
- Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies (2010) (42)
- The genomic landscape of epithelioid sarcoma cell lines and tumours (2016) (41)
- A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases (2019) (41)
- Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines (2020) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (2014) (41)
- Genetic Screening for Familial Gastric Cancer (2004) (40)
- Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities (2020) (39)
- Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis (2021) (39)
- Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome Sequencing (2015) (39)
- Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. (2008) (39)
- Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study (2008) (39)
- Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. (2005) (38)
- TERT promoter mutation in adult granulosa cell tumor of the ovary (2018) (38)
- YWHAE-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin-embedded tumor. (2013) (38)
- New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up (2008) (37)
- SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models. (2020) (37)
- Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis (2015) (37)
- Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. (2011) (37)
- Ovarian Cellular Fibromas Lack FOXL2 Mutations: A Useful Diagnostic Adjunct in the Distinction From Diffuse Adult Granulosa Cell Tumor (2013) (37)
- Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients (2008) (37)
- Better therapeutic trials in ovarian cancer. (2014) (37)
- Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer (2020) (36)
- Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. (2013) (36)
- Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas (2015) (36)
- Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). (2006) (36)
- Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target (2019) (34)
- DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors (2019) (34)
- ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. (2014) (34)
- Clear cell carcinomas of the ovary and kidney: clarity through genomics (2018) (34)
- BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer (2016) (33)
- A current perspective on the pathological assessment of FOXL2 in adult‐type granulosa cell tumours of the ovary (2014) (33)
- Pregnancy after prophylactic total gastrectomy (2010) (33)
- Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome (2020) (32)
- Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas (2014) (32)
- Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. (2006) (32)
- Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines (2008) (31)
- A structured latent model for ovarian carcinoma subtyping from histopathology slides (2017) (30)
- β‐Catenin (CTNNB1) gene amplification: A new mechanism of protein overexpression in cancer (2005) (30)
- Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience (2016) (30)
- Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research (2013) (30)
- Hereditary diffuse gastric cancer. (2010) (29)
- Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. (2018) (29)
- Using next‐generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities (2011) (29)
- Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
- Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis (2019) (29)
- ARID1A regulates R-loop associated DNA replication stress (2020) (27)
- Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE) (2020) (27)
- The tubal hypothesis of ovarian cancer: caution needed. (2011) (27)
- DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics (2019) (26)
- Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma (2015) (26)
- APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. (2017) (25)
- Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020) (25)
- Catenin Family Genes Are Not Commonly Mutated in Hereditary Diffuse Gastric Cancer (2012) (25)
- Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation (2016) (24)
- FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. (2017) (24)
- Caspase-1α Is Down-regulated in Human Ovarian Cancer Cells and the Overexpression of Caspase-1α Induces Apoptosis (2005) (24)
- Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva (2017) (24)
- Markers of T Cell Infiltration and Function Associate with Favorable Outcome in Vascularized High-Grade Serous Ovarian Carcinoma (2013) (23)
- Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. (2016) (23)
- Assignment1 of the E-cadherin gene (CDH1) to chromosome 16q22.1 by radiation hybrid mapping (1999) (23)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Immunohistochemical expression of neurotrophic tyrosine kinase receptors 1 and 2 in lung carcinoma: potential discriminators between squamous and nonsquamous subtypes. (2011) (22)
- Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. (2015) (22)
- Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification? (2011) (22)
- Examining indicators of early menopause following opportunistic salpingectomy: A cohort study from British Columbia, Canada. (2020) (21)
- MyD88 and TLR4 Expression in Epithelial Ovarian Cancer (2018) (21)
- FOXL2 Mutation is Absent in Uterine Tumors Resembling Ovarian Sex Cord Tumors (2015) (20)
- Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours (2020) (20)
- Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. (2014) (20)
- Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition (2015) (20)
- Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma (2021) (19)
- Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci (2017) (19)
- Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits (2017) (19)
- A new method for characterization and epitope determination of a lupus anticoagulant-associated neutralizing antiprothrombin antibody. (1997) (18)
- Germline deletion of ETV6 in familial acute lymphoblastic leukemia. (2019) (18)
- Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention (2022) (18)
- Adult granulosa cell tumour‐like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status (2014) (18)
- The molecular pathology of cancer: from pan‐genomics to post‐genomics (2018) (18)
- Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada (2018) (18)
- Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer (2021) (18)
- Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes (2010) (18)
- PIK 3 CA and PIK 3 CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor – Positive Breast Cancer (2009) (18)
- Boveri at 100: Theodor Boveri and genetic predisposition to cancer (2014) (17)
- Caspase-1alpha is down-regulated in human ovarian cancer cells and the overexpression of caspase-1alpha induces apoptosis. (2005) (17)
- A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention (2018) (16)
- Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation (2017) (16)
- Using Somatic Mutations to Guide Treatment Decisions: Context Matters. (2015) (16)
- Periodic Acid-Schiff Is Superior to Hematoxylin and Eosin for Screening Prophylactic Gastrectomies From CDH1 Mutation Carriers (2010) (16)
- Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. (2012) (15)
- Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses (2020) (15)
- Adult‐type granulosa cell tumor of the ovary: a FOXL2‐centric disease (2021) (15)
- Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction (2016) (15)
- DICER1 hot‐spot mutations in ovarian gynandroblastoma (2018) (15)
- Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research (2013) (15)
- Amplified in breast cancer 1 expression in breast cancer (2008) (14)
- The utility of color normalization for AI‐based diagnosis of hematoxylin and eosin‐stained pathology images (2021) (14)
- Redefinition of familial intestinal gastric cancer: clinical and genetic perspectives (2020) (14)
- International Endocervical Adenocarcinoma Criteria and Classification (IECC): An Independent Cohort With Clinical and Molecular Findings. (2021) (14)
- Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery (2019) (14)
- Abstract A27: The ovarian tumor tissue analysis (OTTA) consortium (2013) (14)
- Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project. (2004) (13)
- Automatic Diagnosis of Ovarian Carcinomas via Sparse Multiresolution Tissue Representation (2015) (13)
- It sounded like a good idea at the time. (2012) (13)
- The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity (2020) (13)
- Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. (2022) (13)
- Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. (2020) (12)
- c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract (2019) (12)
- The testosterone-dependent and independent transcriptional networks in the hypothalamus of Gpr54 and Kiss1 knockout male mice are not fully equivalent (2011) (12)
- Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas (2007) (12)
- Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. (2020) (12)
- Mechanisms of monozygotic (MZ) twinning: A possible role for the cell adhesion molecule, E‐cadherin (2003) (12)
- Distinct developmental trajectories of endometriotic epithelium and stroma: implications for the origins of endometriosis (2018) (12)
- Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. (2007) (12)
- p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns (2020) (12)
- Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type (2020) (11)
- A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants (2019) (11)
- LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. (2017) (11)
- Small‐Cell Carcinoma of the Endometrium (1994) (11)
- Improving response to progestin treatment of low-grade endometrial cancer (2020) (11)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
- Epithelio-mesenchymal transition in a neoplastic ovarian epithelial hybrid cell line. (2004) (10)
- Molecular characterization of a population-based series of endometrial stromal sarcomas in Kuwait. (2014) (9)
- Cancer genomics: why rare is valuable (2015) (9)
- Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. (2022) (9)
- Clinically-inspired automatic classification of ovarian carcinoma subtypes (2016) (9)
- DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. (2019) (9)
- Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. (2016) (9)
- p 53 Is Positively Regulated by miR-542-3 p (2014) (9)
- The coming 15 years in gynaecological pathology: digitisation, artificial intelligence, and new technologies (2020) (8)
- Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study (2014) (8)
- Loss of Sprouty2 in human high‐grade serous ovarian carcinomas promotes EGF‐induced E‐cadherin down‐regulation and cell invasion (2015) (8)
- Accelerating type‐specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high‐throughput tool for case review (2013) (8)
- Single-cell genomic variation induced by mutational processes in cancer (2022) (8)
- Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling: A Prospective Study Comparing Cytology, Frozen Section, and Core Biopsies to Full Pathologic Examination (2015) (8)
- [Prophylactic gastrectomy in patients with deleterious E-cadherin gene mutation]. (2001) (8)
- Whole proteome analysis of mesonephric-derived cancers describes new potential biomarkers. (2020) (7)
- Characterization of the intronic portion of cadherin superfamily members, common cancer orchestrators (2012) (7)
- Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia. (2019) (7)
- Clinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancer (2005) (7)
- Modelling hereditary diffuse gastric cancer initiation using transgenic mouse‐derived gastric organoids and single‐cell sequencing (2021) (7)
- Targeted Molecular Sequencing of Recurrent and Multifocal Non-HPV-associated Squamous Cell Carcinoma of the Vulva. (2020) (7)
- Genomic analysis of a rare human tumor (2010) (7)
- The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis (2004) (7)
- Opportunistic salpingectomy: the way forward-response to Steven Narod. (2013) (7)
- Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles (2019) (6)
- [Hereditary diffuse gastric cancer (HDGC): presentation of a family with a new mutation of the CDH1 gene]. (2007) (6)
- Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of In Vivo Fallopian Tube Electroporation and CRISPR-Cas9–Mediated Genome Editing (2021) (6)
- Mutation Discovery in Regions of Segmental Cancer Genome Amplifications with CoNAn-SNV: A Mixture Model for Next Generation Sequencing of Tumors (2012) (6)
- 4 Refining pathologic interpretation of endometrial carcinomas: lessons learned from a nationwide study in a new era of molecular classification (2020) (6)
- Screening of symptomatic women for ovarian cancer. (2012) (6)
- Re-expression of SMARCA4/BRG1 in Small Cell Carcinoma of Ovary, Hypercalcemic Type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism. (2020) (6)
- Changing Clinical Practice: Evaluation of Implementing Recommendations for Opportunistic Salpingectomy in British Columbia and Ontario (2018) (6)
- Use of Immunohistochemical Markers (HNF-1β, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction (2019) (6)
- Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization (2020) (6)
- Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer (2020) (6)
- Advances in Brief Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression (2004) (5)
- Deep learning-based histotype diagnosis of ovarian carcinoma whole-slide pathology images (2022) (5)
- Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes (2022) (5)
- Synthesis of diagnostic quality cancer pathology images (2020) (5)
- Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas (2021) (5)
- Surgical staging of early stage epithelial ovarian cancer. (2011) (5)
- Categorization of cancer through genomic complexity could guide research and management strategies (2015) (5)
- DNA Methylation Profiles of Ovarian Clear Cell Carcinoma (2021) (5)
- Non-coding Somatic Mutations Converge on the PAX8 Pathway in Epithelial Ovarian Cancer (2019) (5)
- Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. (2023) (4)
- Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
- Abstract POSTER-BIOL-1349: The oncogenic role of DICER1 RNase IIIb domain mutations in ovarian sertoli-leydig cell tumors (2015) (4)
- Molecular Pathology of Ovarian Carcinomas. (2011) (4)
- Cancer Therapy : Clinical IL 6-STAT 3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer (2011) (4)
- Enhanced GAB 2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI 3 K Inhibition (2015) (4)
- STING pathway expression in low‐grade serous carcinoma of the ovary: an unexpected therapeutic opportunity? (2021) (4)
- Dicer and Drosha in ovarian cancer. (2009) (4)
- Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes (2022) (4)
- Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status (2021) (4)
- Single-cell transcriptomic analysis of endometriosis (2023) (4)
- Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition (2017) (4)
- Expression of L1 retrotransposon open reading frame protein 1 (L1ORF1p) in gynecologic cancers. (2019) (4)
- Scientific paper Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma (2006) (4)
- Hereditary diffuse gastric cancer: Natural history, pathology, screening limitations, and prophylactic total gastrectomy in CDH1 mutation carriers (2007) (4)
- Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate (2008) (3)
- Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. (2017) (3)
- Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. (2016) (3)
- Tumor Type and Substage Predict Survival in Stage I and Ii Ovarian Carcinoma: Insights and Implications (2010) (3)
- The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies (2022) (3)
- FOXL2 in adult‐type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene? (2021) (3)
- Familial gastric polyposis and diffuse carcinoma: a new hereditary gastric cancer syndrome not linked to E-cadherin (1999) (3)
- The identification of Lynch syndrome in British Columbia. (2009) (3)
- Profiling the immune landscape in mucinous ovarian carcinoma. (2022) (3)
- The interface of malignant and immunologic clonal dynamics in high-grade serous ovarian cancer (2017) (3)
- 26 - Expression of the ETV6-NTRK3 Gene Fusion in Human Secretory Breast Carcinoma (2002) (2)
- A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention (2018) (2)
- Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary (2018) (2)
- Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type (2019) (2)
- Derangement of p53 and MDM2 is involved in transformation of differentiated into anaplastic thyroid cancer. (2006) (2)
- Classification of Epithelial Ovarian Carcinoma Whole-Slide Pathology Images Using Deep Transfer Learning (2020) (2)
- Abstract AP12: CYSTEINE METABOLISM IN CLEAR CELL OVARIAN CANCER (2017) (2)
- Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer (2021) (2)
- Proteomic Analysis of Transitional Cell Carcinoma-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma. (2020) (2)
- Histotype-specific analysis of acid ceramidase expression in ovarian cancer (2020) (2)
- Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer (2020) (2)
- Reply to “An alternative miRISC targets a cancer‐associated coding sequence mutation in FOXL2” (2021) (2)
- Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma (2021) (2)
- A cellular and molecular portrait of endometriosis subtypes (2021) (2)
- A Marker of Blasts in Acute Leukemia (2016) (2)
- Lapatinib or trastuzumab with taxane therapy as first-line treatment in metastatic breast cancer (MBC): A biomarker analysis in NCIC CTG MA.31. (2014) (2)
- Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci (2017) (2)
- Plus : development and validation of a prognostic model for early breast cancer that includes HER 2 (2012) (2)
- Phyllis Jean McAlpine, Ph.D, FCCMG (1999) (1)
- Diagnostic uncertainty in the interpretation of small atypical acinar lesions of prostate. (2010) (1)
- Reply to Perner and Rubin (2008) (1)
- Invasive breast cancer clinical outcome is predicted by a novel bright-field assay for the simultaneous detection of HER2 gene amplification and protein expression (SILVERFISH). (2004) (1)
- Abstract 5610: Circulating tumor DNA: FOXL2 402C-G mutation can be identified in plasma from adult granulosa cell tumor patients with recurrent disease (2014) (1)
- The use of whole-genome sequencing in therapeutic for decision making in patients with advanced malignancies. (2014) (1)
- Molecular subtype stratified response to adjuvant therapy in endometrial cancer (086) (2022) (1)
- The proteome of clear cell ovarian carcinoma (2022) (1)
- The impact of HER2 positivity on survival in metastatic gastric and GEJ cancer. (2012) (1)
- 2. Survival Impact of HER-2/Neu, Cox-2, Urokinase Plasminogen Activator (upa), Cytokeratin 17/5,6 and other Markers with Long-Term Outcome of Early Breast Cancer. Report from the British Columbia Tissue Micro-Array Project (BCTMAP) (2003) (1)
- Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
- expression of GPR54 and KiSS1 in human breast cancer (2006) (1)
- Abstract LB-038: Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type (2020) (1)
- Significance of p53 and presence of differentiated vulvar intra-epithelial neoplasia (dVIN) at resection margin in early stage human papillomavirus-independent vulvar squamous cell carcinoma (2022) (1)
- Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic (2022) (1)
- DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer (2012) (1)
- Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms (2015) (1)
- Abstract 3422: The influence of genetic and clinical factors on the outcome following a diagnosis of small cell carcinoma of the ovary, hypercalcemic type (2016) (1)
- Abstract LB-324: Genomic consequences of aberrant DNA repair stratify ovarian cancer histotypes (2016) (1)
- Abstract 5381: Therapeutic potential of HDAC inhibitors in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (2015) (1)
- Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas (2014) (1)
- Abstract 1282: Genetic basis of hereditary gastric cancer: Beyond the CDH1 locus (2014) (1)
- Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020) (1)
- Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor. (2019) (1)
- A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation (2014) (1)
- Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer (2021) (1)
- A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer. (2018) (1)
- Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer. (2006) (1)
- p53-Abnormal "Fields of Dysplasia" in Human Papillomavirus-Independent Vulvar Squamous Cell Carcinoma Impacts Margins and Recurrence Risk. (2023) (1)
- Oncogenomics: Molecular approaches to cancer edited by Charles and David Duggan. Wiley-Liss, Hoboken, NJ, 2004. (2005) (1)
- Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line (2020) (1)
- Opportunistic salpingectomy between 2011 and 2016: a descriptive analysis (2022) (1)
- Whole-genome DNA and RNA sequencing in patients with metastatic colorectal cancer (mCRC). (2014) (1)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
- Abstract 4318: Identifying drivers of SMARCA4/BRG1-deficient SCCOHT tumorigenesis by integrative multi-omic analysis (2018) (1)
- 0111: Epigenetic Loss of Brca1 is Common in High-Grade Serous Ovarian Carcinomas, But Not in Other Histopathologic Subtypes of Ovarian Carcinoma (2006) (1)
- Author ' s response to reviews Title : HER 2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy (2009) (1)
- Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study (2022) (1)
- Lynch syndrome-chasing a better ascertainment rate in British Columbia (2010) (1)
- Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type (2019) (0)
- Abstract GMM-047: GENOMIC CHARACTERIZATION OF ADULT-TYPE GRANULOSA CELL TUMORS: IMPLICATIONS FOR PATHOGENESIS AND TREATMENT OF RECURRENT DISEASE (2019) (0)
- Abstract 4542: Development of a one-step molecular classifier for endometrial carcinoma using an amplicon-based gene panel and next generation sequencing technology (2023) (0)
- PopulationDistributionofLifetimeRiskofOvarian Cancer in the United States (2015) (0)
- Author's response to reviews Title: Use of Immunohistochemical Markers can Refine Prognosis in Triple Negative Breast Cancer Authors: (2007) (0)
- Rare cancers 1 Rare cancers: a sea of opportunity (2016) (0)
- Abstract B09: Single-cell RNA sequencing of normal endometrial organoids uncovers novel cell-type markers for prognostication of primary tumor samples (2020) (0)
- Abstract PR03: Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma (2018) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Loss of ARID1A is a frequent event in clear cell and endometrioid ovarian cancers (2011) (0)
- FBxW7 as a predictor of outcomes in ovarian cancer (2013) (0)
- Abstract A17: FBxW7 duality in ovarian cancer: Novel insight into ovarian cancer pathogenesis (2013) (0)
- Abstract 455: Hypoxia induced carbonic anhydrase IX is essential for the growth and metastasis of breast tumors (2010) (0)
- The genomic landscapes of high grade serous ovarian cancers: Contrasting long term survivors and "platinum-resistant" disease (2015) (0)
- Author response: Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism (2020) (0)
- 46INEMERGING MOLECULAR TARGETS IN GYNAECOLOGICAL CANCER. (2014) (0)
- Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Abstract LB-130: Abnormal expression of SWI/SNF chromatin remodeling complex genes in lung cancer (2011) (0)
- The challenges of finding the gene responsible for a rare, autosomal dominant gastric cancer susceptibility syndrome (2012) (0)
- Abstract 3671: Targeting SLC2A1 and SLC38A2-mediated metabolic shift in SMARCA4/A2-dual deficient cancer (2023) (0)
- A new reason not to smoke. (1997) (0)
- DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation (2020) (0)
- Abstract A18: Defining ovarian mucinous tumors: Cancer genes and heterogeneity (2013) (0)
- Abstract AP09: GENOMIC ALTERATIONS IN ENDOMETRIOSIS (2017) (0)
- Abstract B17: Modeling ovarian cancer in mice using in vivo electroporation and CRISPR-mediated genome editing (2020) (0)
- L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile (2018) (0)
- Abstract 4283: Whole genome sequencing is superior to cancer panels to aid in decision-making in patients with advanced malignancies (2014) (0)
- Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer. (2018) (0)
- Shc proteins predict outcome in treatment-naïve breast cancer patients: Do they also predict chemotherapy benefit? (2006) (0)
- Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci (2022) (0)
- 231 Whole genome analysis in a population-based cancer system: Results from sequencing >100 metastatic cancer patients (2015) (0)
- Identification of a novel subtype of endometrial cancer with unfavorable outcome using artificial intelligence-based histopathology image analysis. (2022) (0)
- Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer. (2023) (0)
- Year Excellence in Education Excellence in Basic Science Research Excellence in Clinical or Applied Research Service to the University & Community Overall Excellence Outstanding Contributions by a Senior Faculty Member Overall Excellence - Early Career Overall Excellence - Senior Faculty (2015) (0)
- Abstract 5590: Liquid biopsy testing in metastatic or advanced breast cancer patients during the COVID-19 pandemic (2023) (0)
- Abstract IA13: Organoids and model systems: Rare ovarian cancers (2020) (0)
- Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification (2022) (0)
- Abstract AS18: The somatic mutational landscape of endometriosis associated ovarian cancers and precursor lesions (2015) (0)
- Incidence and distribution of HER2-positive gastric and gastroesophageal junction (GEJ) adenocarinomas in British Columbia (BC). (2011) (0)
- THE LANDSCAPE OF RARE CANCER: A SEA OF OPPORTUNITY (2016) (0)
- Abstract IA15: Rarer, yet both interesting and relevant: Other ovarian cancers. (2016) (0)
- Abstract 4279: Method for identifying microsatellite instability high DNA abnormality samples (2023) (0)
- Can we identify a group of breast cancer patients with a good prognosis despite four or more positive (4+) axillary nodes using a tissue microarray (TMA)? (2007) (0)
- Cáncer gástrico difuso hereditario: implicaciones para la oncología quirúrgica profiláctica (2008) (0)
- Cancer genomics: why rare is valuable (2015) (0)
- populations from tumor whole-genome sequence data TITAN : inference of copy number architectures in clonal cell Material Supplemental (2014) (0)
- FBxW7 duality in ovarian cancer: Novel insight into ovarian cancer pathogenesis (2014) (0)
- Autophagy Defects in Skeletal Myopathies (2020) (0)
- Diagnostic and Prognostic Value of TP53 Expression in Ovarian High-Grade Serous Carcinomas (2010) (0)
- Abstract LB-202: The rare, highly malignant small cell carcinoma of the ovary displays common inactivating germline and somatic mutations in the tumor suppressor SMARCA4 (2014) (0)
- Microbial Contribution to the Human Metabolome: Implications for Health and Disease (2020) (0)
- Synchronous stage IA endometrial and ovarian carcinomas share common mutations: implications for tumour evolution and clinical staging (2014) (0)
- Annual Review of Pathology: Mechanisms of Disease Diversity, Mechanisms, and Significance of Macrophage Plasticity (2020) (0)
- 293 Molecular determinants of CDK4 inhibitor activity in low-grade serous ovarian cancer (2019) (0)
- Abstract B39: The origins of endometriosis-associated cancers (2018) (0)
- Abstract 6417: Deciphering aberrant STING pathway and exploring oncolytic viruses therapy in low grade serous ovarian carcinoma (2023) (0)
- Annual Review of Pathology: Mechanisms of Disease Cardiovascular Disease, Aging, and Clonal Hematopoiesis (2020) (0)
- Predicting the performance of a genetic testing service for cancer susceptibility. (2007) (0)
- Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits (2017) (0)
- Abstract AP25: INHIBITION OF HDAC ACTIVITY SELECTIVELY INHIBITS ARID1A–MUTATED OVARIAN CLEAR CELL CARCINOMA THROUGH A NOVEL P53 REGULATORY MECHANISM (2017) (0)
- Results from Ion AmpiSeq Cancer Panel in 200 cases of gastric and gastroesophageal junction cancer. (2013) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention (2022) (0)
- Authors' Reply (2010) (0)
- Benign serous ovarian tumour: a redefining moment? (2012) (0)
- Liver Progenitors and Adult Cell Plasticity in Hepatic Injury and Repair: Knowns and Unknowns (2020) (0)
- Beyond CDH1 Mutations: Causes of Hereditary Diffuse Gastric Cancer (2013) (0)
- Abstract PR07: Synchronous ovarian and endometrial carcinomas: The case for pseudo-metastasis. (2016) (0)
- A new enrichment model for high sensitivity detection and downstream analyses of circulating tumor cells in breast cancer patients. (2008) (0)
- Abstract 223: Identifying gene amplifications in p53 abnormal endometrial carcinomas by shallow whole genome sequencing (2023) (0)
- p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study (2023) (0)
- Abstract 1611: Epithelial-mesenchymal-epithelial transition induced by long term exposure to TGFB1 creates cellular heterogeneity (2016) (0)
- Molecular Pathogenesis of Membranous Nephropathy (2020) (0)
- Abstract NTOC-084: THE PROMISE OF COMBINATIONAL TREATMENT OF HISTONE DEACETYLASE 6 INHIBITOR ACY-1215 AND PROTEASOME INHIBITOR BORTEZOMIB IN SCCOHT (2017) (0)
- Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51 (2020) (0)
- CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2022) (0)
- Brunt et al.—histological evaluation of iron in liver biopsies: relationship to HFE mutations (2001) (0)
- Table 1. [Summary of Molecular Genetic Testing Used in Hereditary Diffuse Gastric Cancer]. (2014) (0)
- Abstract 2215: Detection of novel markers of transitional cell carcinoma of the ovary, the TCC-like variant of high grade serous carcinoma, using proteomics and immunohistochemistry (2017) (0)
- Annual Review of Pathology: Mechanisms of Disease Development of the Intrahepatic and Extrahepatic Biliary Tract: A Framework for Understanding Congenital Diseases (2020) (0)
- Abstract 4967: Investigating the therapeutic efficacy of EO3001 in clear cell carcinoma of the ovary (2023) (0)
- Abstract IA019: Organoids to model endometrial cancer subtypes (2021) (0)
- Abstract IA8: Discovering drivers in rare ovarian cancer subtypes (2013) (0)
- Abstract IA12: The Ovarian Tumour Tissue Analysis Consortium: Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) signature for high-grade serous ovarian cancer (2020) (0)
- Autofluorescence Imaging of Fallopian Tube Carcinogenesis (2010) (0)
- Explorer Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma (2017) (0)
- Abstract B46: DICER1 and FOXL2 mutations correlate with clinicopathologic features of ovarian Sertoli-Leydig cell tumors (2018) (0)
- BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors (2022) (0)
- Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target (2019) (0)
- Rare APC promoter 1B variants in gastric cancer kindreds unselected for fundic gland polyposis (2020) (0)
- Abstract 2482: On the verge of metastasis: CTH defines a cell-state-dependent adaptive response to microenvironmental stresses (2023) (0)
- Abstract B04: RAD51 expression as a biomarker of homologous recombination deficiency in ovarian cancer (2017) (0)
- Abstract 605: The clinical outcome of patients with FOXL2 402C->G mutation positive adult-type Granulosa Cell Tumor of the ovary - a population based study with analysis of tissue and plasma ctDNA (2015) (0)
- Abstract B25: SMARCA4/BRG1 and AP-1 co-regulate an epithelial-like signature in small-cell carcinoma of ovary, hypercalcemic type (SCCOHT) (2020) (0)
- Supplement to: cancer associated mutations in non-cancer associated endometriosis (2017) (0)
- Abstract A07: Sequential ctDNA analysis detected preclinical relapse in patients with metastatic colorectal cancer from the Exactis trial (NCT00984048) (2020) (0)
- Abstract DPOC-014: BEYOND CODING MUTATIONS: USING RETROTRANSPOSONS TO PREDICT OVARIAN CANCER DEVELOPMENT (2017) (0)
- Auto fl uorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium : A promising step towards screening and early detection (2011) (0)
- Abstract PR002: Global proteomic profiling of endometrial carcinomas identify prognostic markers (2021) (0)
- Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas (2015) (0)
- Abstract LB-312: The somatic mutational landscape of ovarian clear cell carcinoma and its precursor lesions (2014) (0)
- 1570ODEMONSTRATION OF TEMPORAL HETEROGENEITY IDENTIFIED BY GENOME SEQUENCING AND THE POTENTIAL EFFECT ON TREATMENT DECISIONS FOR ADVANCED CANCER PATIENTS. (2014) (0)
- Abstract AP32: THE METHYLTRANSFERASE EZH2 IS A VULNERABLE TARGET IN SMALL CELL CARCINOMA OF THE OVARY, HYPERCALCEMIC TYPE (SCCOHT) (2017) (0)
- Abstract 1238: Targeting the platelet derived growth factor receptor (PDGFR) with the receptor tyrosine kinase inhibitor ponatinib in small cell carcinoma of the ovary, hypercalcemic type (2017) (0)
- iron overload: identification of a novel TfR2 mutation Transferrin receptor 2 (TfR2) and HFEmutational analysis in non-C282Y (2013) (0)
- THE ASSOCIATION OF LOBULAR BREAST CANCER WITH GERMLINE MUTATIONS OF CDH1 (2008) (0)
- Abstract B30: The effect of OCP use on the incidence of precancerous p53 lesions in fallopian tube fimbria (2020) (0)
- Abstract 4899: Investigating mutation co-operativity in early tumorigenesis of low-grade serous ovarian carcinoma with organoid model system and single-cell RNA sequencing (2020) (0)
- Synthetic lethality when combining phosphoinositide 3-kinase alpha and beta catalytic subunit-directed RNAi and estrogen deprivation for estrogen receptor positive breast cancer: implications for clinical trial design with pharmacological inhibitors. (2009) (0)
- Abstract POSTER-TECH-1119: Phylogenetic portraits of high grade serous ovarian cancer (2015) (0)
- Genomic characterization of DICER1-associated neoplasms uncovers molecular classes (2023) (0)
- Annual Review of Pathology: Mechanisms of Disease Enabling Precision Oncology Through Precision Diagnostics (2020) (0)
- Modeling High-grade serous ovarian carcinoma using a combination of in vivo electroporation and CRISPR/Cas9 mediated genome editing (2021) (0)
- Abstract 3673: Targeting the epigenome of small cell hypercalcemic carcinoma of the ovary, hypercalcemic type (SCCOHT) (2018) (0)
- Abstract B08: Genomics analyses of less common epithelial ovarian cancer subtypes. (2016) (0)
- Abstract 544: Recurrent DICER1 hotspot mutations in endometrial cancer and their impact on microRNA biogenesis (2014) (0)
- Practical application of whole genome and transcriptome tumour analysis to guide chemotherapy decision-making for patients with advanced cancers. (2013) (0)
- Animal Models of Metastasis (2015) (0)
- Abstract PR13: TERT is frequently mutated in adult-type granulosa cell tumors of the ovary compared to other malignant sex cord-stromal tumors (2018) (0)
- Stromal mast cells as a favorable prognostic marker in early breast cancer (2004) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Abstract AP11: IDENTIFYING FUNCTIONAL NONCODING SOMATIC MUTATIONS IN OVARIAN CANCER (2019) (0)
- Abstract A25: PPP2R1A mutations affect PP2A complex formation, and novel protein interactions in gynecological carcinoma cell lines (2013) (0)
- Abstract GMM-030: MODELS AND ANALYTIC TECHNIQUES OF MULLERIAN TISSUE-DERIVED ORGANOIDS (2019) (0)
- Abstract LB-173: Genome analysis informs chemotherapy decision-making in patients with advanced malignancies. (2013) (0)
- Annual Review of Pathology: Mechanisms of Disease Contributions of Eosinophils to Human Health and Disease (2020) (0)
- From biobank and data silos into a data commons: convergence to support translational medicine (2021) (0)
- 597 Using an in Vitro Model of Epithelial-Mesenchymal-Epithelial Transitions to Uncover Novel Biological Mechanisms (2012) (0)
- Abstract B10: FOXL2 402C>G mutation can be identified in the circulating tumor DNA of patients with adult-type granulosa cell tumor. (2016) (0)
- Corrigendum: Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 (2014) (0)
- DNA Methylation Pro fi les of Ovarian Clear Cell Carcinoma (2021) (0)
- Author ' s response to reviews Use of Immunohistochemical Markers can Refine Prognosis in Triple Negative Breast Cancer (2007) (0)
- Abstract GMM-020: CELL OF ORIGIN, MUTATION AND MICROENVIRONMENT: MODELING EARLY EVENTS OF ENDOMETRIOSIS ASSOCIATED CANCERS (2019) (0)
- Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
- Abstract 924: Identification of somatic mutations of the PPP2R1A gene in subtypes of endometrial and ovarian carcinomas (2011) (0)
- Abstract NTOC-090: TARGETING AND EFFICACY OF THE RECEPTOR TYROSINE KINASE INHIBITOR PONATINIB IN SMALL CELL CARCINOMA OF THE OVARY, HYPERCALCEMIC TYPE, WORKS THROUGH INHIBITION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) (2017) (0)
- The National Access Project for Cancer Testing (2014) (0)
- Carbonic anhydrase IX, a biomarker of hypoxia, as a poor prognostic factor in invasive breast cancer: results from 321 cases in a tissue microarray series. (2003) (0)
- Abstract B23: CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines (2020) (0)
- Prevalence of CDH1 germline mutations in subjects with early onset or familial lobular breast cancer, a multicenter collaboration. (2016) (0)
- Abstract B22: Capturing L1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers as a way to track tumor development (2018) (0)
- Re: Brunt et al.—histological evaluation of iron in liver biopsies: relationship to HFE mutations (2001) (0)
- 6 Variation in practice in endometrial cancer (EC); can molecular classification direct care and reduce costs associated with management? (2020) (0)
- The driver landscape of sporadic chordoma (2017) (0)
- Shared heritability and functional enrichment across six solid cancers (2019) (0)
- 192. HER-3 Expression Shows Prognostic Utility for Breast Cancer Survival: A Study of 4046 Patients (2009) (0)
- Validation of FOXA1 as a Prognostic Marker in Breast Cancer in a Large Population-Based Tissue Microarray. (2009) (0)
- Abstract 395: Identifying the functional drivers of noncoding somatic mutations in ovarian cancer (2018) (0)
- The Kisspeptin and GPR54 ligand-receptor pair are associated with favorable prognosis and clear cell subtype in human ovarian carcinoma (2007) (0)
- A case of the utilization of genomic information in the management of metastatic colorectal cancer. (2013) (0)
- Abstract 4289: Using the right tools: A catalog of ovarian cancer cell lines by subtype (2011) (0)
- Abstract B14: Rapid RNA-based histotyping of ovarian carcinomas (2013) (0)
- High Frequency of Ovarian Cyst Development in Vhl2B/+;Snf5+/- Mice. (2018) (0)
- Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts). (2013) (0)
- Abstract IA19: Granulosa cell and other rare ovarian cancers: Genomic-derived diagnostics and emergent management strategies (2018) (0)
- From Subtype Specific Biologic Insights to Subtype Specific Ovarian Cancer Control. (2012) (0)
- Hereditary diffuse gastric cancer in the developing world: A Jordanian family. (2010) (0)
- Personalized oncogenomics (2010) (0)
- Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers (2018) (0)
- Incidence and distribution of HER2-positive gastric and gastroesophageal junction (GEJ) adenocarinomas in British Columbia (BC). (2011) (0)
- HER-2 gene amplification in circulating tumor cells (CTCs): Concordance with amplification status in primary breast cancers and metastatic lesions. (2009) (0)
- Molecular profiling of endometrioid ovarian carcinomas (2019) (0)
- Abstract 3381: TERT promoter mutation in granulosa cell tumours of the ovary: Prevalence and prognostic significance (2017) (0)
- Abstract LB-271: Benign ovarian serous tumors: A redefining moment (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David George Huntsman?
David George Huntsman is affiliated with the following schools:
